The document provides an overview of the emerging longevity industry, including key players, sectors, trends and future reports. It discusses leading companies, investors, conferences and the landscape of geroscience, regenerative medicine, gene therapy and P3 medicine. It also outlines topics to be explored in more detail in upcoming reports, such as the business of longevity, industry markets, clinics and novel investment approaches. Interactive network maps and databases will visualize specializations and interactions between stakeholders in the longevity field.

1. The Business of Longevity
The Paradigm Shift from Treatment to Prevention

2. Longevity Industry Landscape Overview Volume I: The Business of Longevity
Markets
Sectors
Companies
Investors
Influencers
1
2
3
4
5
6 Trends

3. The topics covered in the following infographic preview, which is a part of a joint project between the Biogerontology Research
Foundation (BGRF), Deep Knowledge Life Sciences (DKLS), and the Aging Analytics Agency are explored in more far greater detail in
our soon to be released reports:
● Longevity Industry Landscape Overview Volume I: The Business of Longevity
● Longevity Industry Landscape Overview Volume II: Geroscience, Policy & Economics
● Longevity.International: Our interactive online platform and database, which employs automated chart, graph, and network
map creation software to visualize the data contained in all of our reports.
Table of Contents
1. Leading Companies, Investors, and Influencers
1.1. Top companies, VC Investors, VC Firms, Influencers,
Research Institutions & Scientists
1.2. Landmark Longevity Conferences
1.3. Geroscience, Regenerative Medicine, Gene Therapy &
P3 Medicine Company Landscape
1.3.1. Top 100 Companies
1.4. Geroscience, Regenerative Medicine and P3 Medicine
Landscape
1.4.1 Top 100 VC Firms
2. Longevity International Online Report &
Interactive Database
2.1. Interactive Network Maps
2.2 Investor-Company Interaction Map
3. Longevity Industry Market Landscape Overview
3.1. Longevity Industry and Subsectors
3.1.1. Regional Distribution by Sector
3.2. Regenerative Medicine Overview
3.3. P3 Medicine Overview
3.4. Gene Therapy & Drug Delivery Overview
4. P3 Medicine Clinics: Personalized, Precision,
Preventative
4.1. P3 Medicine Clinic platform Overview
4.2. P3 Medicine Market - Present & Projected
4.3. P3 Technologies Completion Timeline
5. Novel approaches to Longevity Investments
5.1. Novel Investment Strategies & Special Financial
Vehicles
5.2. Longevity Finance Industry Roadmap

4. The following section gives an overview of the longevity industry's leading companies, investors
and influencers, aggregating the main and most active players and shareholders in the emerging
longevity industry.
Topics covered include:
● Leading Influencers and Top 10 Longevity Entrepreneurs, Investors, Scientists, Companies
and Investors
● Leading Longevity Companies
● Leading Longevity Investment Firms

5. Insilico Medicine
Top Longevity Investors Top Longevity Venture FundsTop Longevity Companies

6. Top Longevity Companies, Venture Capital Investors, Venture Capital Firms, Research Institutions, Scientists & Influencers
Aubrey de Grey Nir Barzilai
Dr. Felipe Sierra
Brian Kennedy
Joao Pedro de
Magalhaeres
Top Longevity Influencers Top Longevity Scientists
Sergey Brin
Larry
Page
Martine
Rothblatt
Larry
Ellison
George Church
Ray
Kurzweil
Bill Maris Alex
Zhavoronkov
J. Craig
Venter
Michael West
David
Sinclair
Top Longevity Investors
Bryan Johnson
Peter Thiel Jeff Bezos
Dmitry Kaminskiy
Jim Mellon
Finian Tan
Nathaniel
David
Cynthia Kenyon

7. Top Research InstitutionsTop Gene Therapy CompaniesTop Reg Med Companies
Top Longevity Companies, Venture Capital Investors, Venture Capital Firms, Research Institutions, Scientists & Influencers

8. Top Longevity Venture FundsTop P3 Medicine Companies Top Longevity Companies
Insilico Medicine
Top Longevity Companies, Venture Capital Investors, Venture Capital Firms, Research Institutions, Scientists & Influencers

9. Landmark Longevity Conferences
The Economist: The
Business of Longevity
and Ageing Societies
2016
The Economist: The
Business of Longevity
and Ageing Societies
2016

10. Landmark Longevity Conferences
Basel Life Sciences
Aging Forum
Davos Longevity
Conference
Next Year:
AI &
Blockchain
in Ageing &
Healthcare

11. Grand Brands in Support of Longevity

12. Geroscience, Regenerative Medicine, P3 Medicine & Gene Therapy Company Landscape
Regenerative
Medicine
P3 Medicine

13. Geroscience, Regenerative Medicine, P3 Medicine & Gene Therapy Company Landscape
Gene Therapy Geroscience

14. Top 100 Geroscience, Regenerative Medicine, P3 Medicine & Gene Therapy Companies
1 Abeona Therapeutics
2 AgeX
3 Alkahest
4 Antoxis
5 Athersys
6 Atlas Regeneration
7 AxoGen
8 Axonia Medical
9 BGI
10 BIOAGE Labs
11 BioLife Solutions
12 BioMarin
13 BioMarker Pharmaceuticals
14 BioTime
15 BioViva USA
16 Calico
17 Cell Habitats
18 CellAge
19 Celularity
20 Centagen
21 Centrillion Technologies
22 Chipscreen
23 Chronos Therapeutics
24 CohBar
25 Color Genomics
26 Cyfuse Biomedical
27 Cytori
28 Draxis Health
29 Elysium Health
30 Emulate
31 Epitracker
32 Everist Health
33 Everon Biosciences
34 Evox Therapeutics
35 Fronteo
36 GC-Rise Pharma
37 Genescient Corp
38 Genos
39 GenSight Biologics
40 Genzyme Corporation
41 Geron
42 Harbour Biomed
43 Hua Medicine
44 Human Longevity Inc.
45 Ichor Therapeutics
46 Inception Sciences
47 Insilico Medicine
48 Interprotein
49 Juventas Therapeutics
50 Kailos Genetics
51 Leadhexa Biotechnologies
52 LifeGen
53 Longevity Biotech
54 MacuCLEAR
55 Mesoblast
56 Metabomed
57 Mitobridge
58 Mitotech
59 Navitor
60 NovaHep
61 NovaDip Biosciences
62 NuSirt
63 Oisin Biotechnologies
64 NOX Technologies
65 Orig3n
66 Osiris Therapeutics
67 Orthomolecular Research
68 Oxstem
69 PHIGENIX
70 Pluristem
71 Population Bio
72 Prana Biotechnology
73 Progenitor Therapeutics
74 Proteostasis Therapeutics
75 PureTech Health
76 Retrotope
77 Quark Pharmaceuticals
78 Quincy Bioscience
79 Rapamycin Holdinds
80 ReThink Pharmaceuticals
81 Revance Therapeutics
82 RondinX
83 Samumed
84 Sangui Biotech International
85 Semma Therapeutics
86 Signum
87 Silene Biotech
88 Sierra Sciences
89 SIWA Therapeutics
90 SQZ Biotech
91 TauRx Therapeutics
92 Unity Biotechnology
93 Universal Cells
94 Vault
95 Vericel Corporation
96 Veritas Genetics
97 Videregen
98 Visgeneer
99 Vitruvian Networks
100 Voyager Therapeutics

15. Regenerative Medicine Geroscience
Geroscience, Regenerative Medicine & P3 Medicine VC Landscape

16. P3 Medicine

17. Top 100 Geroscience, Regenerative Medicine, P3 Medicine & Gene Therapy VC Firms
1 ABN AMRO
2 Accuitive Medical Ventures
3 Advantech Capital
4 Alexandria Venture
5 Ally Bridge Group
6 ALS Finding a cure
7 AME Cloud Ventures
8 Amino Capital
9 Ann Arbor SPARK
10 ARCH Venture Partners
11 Arkin Holdings
12 Aspire Capital Partners LLC
13 ATEL Ventures
14 BRCC
15 Brainchild Holdings
16 Cardinal Partners
17 Casdin Capital
18 Cedars Sinai Medical Center
19 Celgene
20 CIRM
21 Cyberdyne
22 Deerfield
23 Deerfield Partners
24 DeNovo Ventures
25 Draper Fisher Jurvetson (DFJ)
26 Easton Capital
27 EcoR1 Capital
28 Eight Roads Ventures
29 Emerson Collective
30 "Essex Woodlands Health Ventures"
31 F-Prime Capital Partners
32 Fidelity Investments
33 First Analysis
34 Flagship Pioneering
35 Forbion Capital Partners
36 Formation 8
37 GE Capital
38 GE Ventures
39 General Catalyst
40 GV
41 Harvest Global Investments
42 Horizon Ventures
43 Illumina
44 Integrale Advisors
45 Inventages Capital Investment inc
46 Jennison Associates
47 Juno Therapeutics
48 Khosla Ventures
49 LabCorp
50 Legend Capital
51 LYZZ Capital
52 Magic Stone Alternative
53 Mayo Clinic Ventures
54 Merck Ventures
55 Mistletoe
56 NanoDimension
57 Nazem and Company
58 New Science Ventures
59 Nivelinvest
60 Odey Asset Management
61 Odey Swan
62 Omega Funds
63 OrbiMed
64 OS Fund
65 Oxford Finance Corporation
66 Oxford Sciences Innovation
67 Partners Innovation Fund
68 Piper Jaffray Private Capital Group
69 Polaris Partners
70 RA Capital Management
71 Ramius Advisors
72 Sanofi-Genzyme BioVentures
73 Shibuya Kogyo
74 Silicon Valley Bank
75 Sino-Alliance International LTD
76 S.R.I.W.
77 Sphera Funds Management
78 Springboard Capital
79 StartUp Health
80 Sutter Hill Ventures
81 SWMF Life Science Fund
82 Syno Capital
83 Synthetic Genomics
84 T. Rowe Price
85 Tan Thay
86 Techammer
87 Techno Venture Management
88 Testudo Funds
89 The Thiel Foundation
90 Third Rock Ventures
91 Toray Engineering
92 TVM Capital
93 TYLT Ventures
94 Venrock
95 Versant Ventures
96 Vertex Ventures
97 Viking Global Investors
98 Vives Fund
99 Warburg Pincus
100 WuXi Healthcare Ventures

18. The following section gives a
preview of several network
diagrams that visualize
specialized interactions
between longevity companies,
investors, non-profits and
research institutions.
They are previews of more
advanced and interactive
network diagrams and maps
that will be featured on the
companion Website
www.Longevity.International
, which aggregates existing
data on the emerging
longevity industry and
allows users to analyze and
visualize trends, events and
interactions between the
main players and
stakeholders of the
longevity industry.

19. Subsequent editions of this report will feature extensive interactive network diagrams
that visualize interactions between companies, investors, academic research
institutions, scientists, influencers and policy makers. The online platform associated
with these reports will also feature an online interactive database that can be used to
generate customizable graphs, charts and network diagrams.
These provide deeper insight into trends and
interactions within the longevity industry and the
geroscience field from the perspective of a
variety of distinct stakeholders. The following are
preliminary examples of such network diagrams.
Multiple arrows from one organization (in this
case investors) to another indicated the number
of separate investments, and the color of the
arrows will be used to indicate the type of
investment (Seed, Series A, Series B, Undisclosed,
etc.).
Examples of Interactive Network Maps

20. Sino Alliance
International
LTD
Hua Medicine Emulate Inc

21. Investors-Companies Interactions

22. The following section gives a general market overview of the
emerging longevity industry and of tangential industries that
complement the emerging longevity industry and that provide
some of the basic techniques and technologies than will be
used within the emerging longevity industry, including the P3
(personalized, precision and preventive) Medicine,
Regenerative Medicine, and Gene Therapy & Drug Delivery
markets.
Topics covered include:
● Regenerative Medicine Market Overview
● P3 Medicine Market Overview
● Gene Therapy & Drug Delivery Market Overview

23. Geroscience
Preventing chronic
disease by slowing
or reversing their
largest risk factor -
biological aging
P3 Med
Personalized and
preventive therapies
that tailor treatments
to specific patient
populations
Reg Med
Cell therapy and
tissue/organ
engineering to
replace diseased
cells and tissues
Gene
Therapy
Reg
Med
P3
Medicine
Gero-
science
Gene
Therapy
Gene insertion or
deletion to correct
disease-associated
mutations
Regional Distribution of Companies in All 4 Sectors

24. USA VS EU
79%
USA
21%
EU
100%
0%
90%
10%
37.5%
62.5%
60%
40%
Geroscience P3 Medicine Reg Med
Gene
Therapy

25. Region Distribution of Top 10 Companies in All 4 Sectors
EUROPE
USA USA
Geroscience P3 Medicine

26. Region Distribution of Top 10 Companies in All 4 Sectors
EUROPE
USA
EUROPE
USA
Reg Med Gene Therapy

30. The following section gives a broad overview of the
emerging P3 (personalized, precision and preventive)
Medicine market, including the core technologies
underlying the market, timelines for the growth and
development of its core technologies, and a roadmap
toward the creation of the optimal P3 Medicine clinic.
Topics covered include:
● Overview of the optimal Model of P3 Clinic
Platform
● Overview of the P3 Medicine Market - Present &
Projected
● Timeline for Completion of Technologies from
100 Companies Underlying optimal P3 Clinic
Platform
● Roadmap Toward the optimal P3 Clinic

31. Overview of the Optimal Model of P3 Medicine Clinic Platform
Exclusive access to advanced
restorative medicine technologies
Healthy lifespan extension and ageing
processes reversal to a young state
Personalized longevity programs
Health management by world
leading experts
Personalisation and precision of
diagnostics, prognostics and
treatment for individual patient
01
02
03
Personalised diagnostics, prognostics and
therapeutics
Virtual human body for health monitoring
Continuous health monitoring by the world
leading experts
Exclusive safe testing of novel therapies
on individual`s stem cells, skin and other
organs

32. Overview of the Optimal Model of P3 Medicine Clinic Platform
Advanced
Diagnostics
Precision
Prognostics
Personalised
Experimentation
Preventative
Treatment
Multi-Omic
Sequencing
Non-invasive
continuous
monitoring
Total-body imaging
Virtual Human
Prognostics
Personalised in
vitro Prognostics
Intelligent in silico
Experimentation
Personalised in vivo
experimentation
on human skin
Gene therapies
Cell therapies
Tissue engineering
Small molecules &
biologics

33. Overview of the P3 Medicine Market - Present & Projected
20%
Preventative and
personalised diagnostics
80%
50%
50%
2016 2026
Preventative and
personalised diagnostics
Treatment of chronic and
Last stage diseasesTreatment of chronic and
Last stage diseases
Paradigm Shift from Treatment to Prevention

34. Market size of key restorative medicine technologies, $B
0
100
200
300
400
2016 2020 2025
Small molecules
and biologics
Stem Cells therapy
Bioinformatics
Next Generation
Sequencing
Gene therapy
(CRISPR)
3D bioprinting
278
171
13
9
4
1.3
435
391
34
25
8
3
194
72
6
4
1
0.7

35. Timeline for Completion of Technologies from 100 Companies Underlying Optimal P3 Clinic Platform
Technology Readiness Level (TRL)
2018 2020 2022
Small
Molecules
and Biologics
Stem Cell
Therapy
Bioinformatics
Next
Generation
Sequencing
Gene
Therapy
(CRISPR)
3D Bioprinting

36. The following section gives an overview of the various methods if
investment in the emerging longevity industry, from traditional
Venture Capital approaches to more optimized and specialized
investment approaches. The section also gives an overview of the
emerging longevity financial services industry likely to emerge in the
wake of advances and the rise of big players within the core longevity
industry, including longevity venture capital funds, longevity hedge
funds, longevity trusts and a new form of banking institution we have
called AgeTech Bank, which leverages the intersection of FinTech
with HealthTech to provide enhanced financial security for elderly
citizens that can expect to witness longer lifespans than they had ever
financially planned for.
Topics covered:
● Overview of the Longevity Finance Industry
● Roadmap Toward the Longevity Finance Industry

37. Novel Investment Strategies and Special Financial Vehicles Specifically Tuned for the Longevity Industry

38. Novel Investment Strategies and Special Financial Vehicles Specifically Tuned for the Longevity Industry

39. Approaches to Investment in the Longevity Industry:
Special Synthetic Financial Vehicles (from Simple to Advanced)
VC approach, betting on very few precisely
chosen but extremely promising start-ups after
very deep due diligence, and to make all bets on
those very few companies
Venture Approach
Broader investments and more diversified portfolio, betting on
competitor’s portfolio companies to minimize
competition-based loss; the most diversified investment
strategy covering all sectors of the longevity industry
Balanced
Investment in a specific sector of the longevity industry,
optimizing skill and experience in a narrow area, more
diversified than the typical venture approach
Specifically Focused
Specifically-optimized synthesis of above approaches,
investing in diverse portfolio of companies while also investing
in competitor’s biggest bets and shorting risky, overhyped
and scientifically-invalidated companies
Special Synthetic Financial Vehicle

40. Approaches to Investment in the Longevity Industry:
Special Synthetic Financial Vehicles (from Simple to Advanced)

41. Longevity VC Fund:
VC Fund focused
on longevity
startups, with deep
scientific expertise in
geroscience
AgeTech Bank:
New generation of
bank for the aging
demographic
combined with
AgeTech and
geroscience based
healthcare services
Longevity Trust:
Trust optimized to
manage clients’
wealth and assets
across an
extended period
of healthy
longevity
Roadmap Toward Longevity Finance Industry
Longevity
Hedgefund:
Hedge fund that
shorts risky and
non-scientific life
science and
longevity
companies via
special synthetic
financial vehicle

42. Longevity
Venture Capital
Fund
AgeTech Bank
Longevity
Hedgefund
Longevity Trust
2018
2018
2019
2020

43. The topics covered in the present preview (part of a joint project between the
Biogerontology Research Foundation, Deep Knowledge Life Sciences and Aging Analytics
Agency) are explored in more detail in our upcoming reports:
● Longevity Industry Landscape Overview Volume I: The Business of Longevity
● Longevity Industry Landscape Overview Volume II: Geroscience, Policy & Economics
● Longevity.International, our interactive online platform and database, which employs
automated chart, graph and network map creation software to visualize the data
contained in our reports.